China Resources Double-Crane Pharmaceutical (SHA:600062) said its pentazocine injection passed the generic drug quality and efficacy consistency evaluation.
The notice was issued by the National Medical Products Administration, according to a Dec. 31 filing with the Shanghai bourse.
Pentazocine is used to treat severe chronic pain and serves as a pre-anesthetic as an auxiliary drug for surgical anesthesia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.